InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a cash balance of approximately $9.6 million as of Dec. 31, 2024, and announced the termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., effective Jan. 23, 2025. Calidi secured $9.5 million in gross proceeds in late 2024 through public offerings, $2.0 million from warrant exercises,…